Novel immune pharmacological approaches for the treatment of bacterial invasive infections

Abstract

The emergency of multiresistant bacterial strains is, likely, one of the main concerns related with the clinical practice´s misuse of antimicrobial (ATM) drugs in human and veterinary medicine. Some of these bacteria are mentioned as follow: community multiresistant Staphylococcus aureus (Ca-MARSA) and, hospitalary multiresistant Staphylococcus aureus (HMARSA), Enterococcus spp. vancomycin resistant genotype vanA, Streptococcus pneumoniae beta lactams resistant and food transmission quinolones resistant Salmonella spp. The re-emergency of pathogens with difficulties to be treated by conventional ATM therapy, i.e Listeria monocytogenes, must also be having into account. The complexity of this situation in clinical practice is reflected in a therapeutic failure with poor patient response and likelihood of death risk. For this reason, new alternatives for helping the conventional ATM therapy will be described in this chapter. The actions of a novel antimicrobial peptide (AP-CECT7121) and a natural immunomodulator, both obtained from a saprophytic environmental strain, Enterococcus faecalis CECT7121 (characterized as probiotic), will here be described as new model of therapeutic strategy for helping the control of some invasive infections.